# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> 48 adverse events occurred in 16 (84%) of 19 participants who received metformin and 48 adverse events occurred in 19 (90%) of 21 participants who received placebo.

## Failed citation traces

- **alias_match** on `C060` (ref=0): alias 'PhenoAge' NOT resolved (drift)

## Panel reviews

### `evidence_auditor` — `reject` (score 3)

Claim C060 failed its alias trace; the term 'PhenoAge' was not resolved, indicating a drift between the claim's terminology and the source evidence. According to the auditor guidelines, a failed trace is grounds for rejection.

**Flagged claims:** C060

### `domain_skeptic` — `reject` (score 3)

The submission suffers from severe sample-size issues that render the claims clinically insignificant, yet they are presented as 'moderate' evidence without necessary caveats. The data is derived from a tiny cohort (n=19 for metformin, n=21 for placebo), which is insufficient to draw meaningful conclusions about safety or efficacy, particularly for a drug as widely used as metformin. 

Furthermore, there is a significant 'off-topic drift' or lack of clarity regarding the primary endpoint. The citation trace explicitly flags a failure to resolve the alias 'PhenoAge', meaning the submission is claiming a specific effect on a biological aging clock without verifying that the source actually measured that specific metric. Presenting a non-significant p-value (p=0.627) from a sample of 40 people as a formal finding without highlighting the study's underpowered nature is a failure of calibration.

**Flagged claims:** C060, C061, C062

### `final_judge` — `reject` (score 3)

I align with both the Evidence Auditor and the Domain Skeptic. The failure to resolve the 'PhenoAge' alias in C060 is a critical technical failure; the submission claims a specific effect on a biological aging metric that the citation trace could not verify in the source text. This constitutes a failure of evidence mapping.

Furthermore, I find the Domain Skeptic's concerns regarding sample size and calibration highly persuasive. Reporting results from a cohort of only 40 participants as 'moderate' evidence without explicit caveats regarding the study's lack of power is misleading. The fact that the p-value is non-significant (p=0.627) further underscores that these findings are clinically insignificant, yet they are presented as formal data points. The combination of technical drift and poor statistical calibration necessitates a rejection.

**Flagged claims:** C060, C061, C062

## References

[27] Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial. (2026). https://doi.org/10.1016/j.eclinm.2026.103874
